The adaptive immune system has the capacity to elicit anti-cancer CD4+ and CD8+ T-cell responses, which are triggered by the presentation of cancer-derived antigens as human leukocyte antigen-binding peptides (HLAp) and their recognition by cognate T-cell receptors. Here, HLA-P is linked to cancer.